BC
NVO

Belmont Capital’s Novo Nordisk NVO Stock Holding History

Belmont Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$2.07K Hold
30
– – ﹤0.01% 162
2025
Q1 		$2.08K Buy
+30
New +$2.48K ﹤0.01% 164
2024
Q3 		– Sell
-588
Closed -$83.9K – 199
2024
Q2 		$83.9K Hold
588
– – 0.02% 150
2024
Q1 		$75.5K Buy
+588
New +$70K 0.02% 115

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Belmont Capital's NVO Position: Q2 2025 in Review

Belmont Capital held its Novo Nordisk (NVO) position steady in Q2 2025 at 30 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #162.

Belmont Capital first reported a position in NVO in Q1 2024 and has held it in 4 quarters since. The position peaked at $83.9K in Q2 2024. 1,482 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Belmont Capital held 30 shares of Novo Nordisk worth $2.07K as of Q2 2025.
  • Belmont Capital left its Novo Nordisk share count unchanged in Q2 2025.
  • Novo Nordisk made up ﹤0.01% of Belmont Capital's portfolio in Q2 2025, its #162 holding.
  • Belmont Capital first reported a position in Novo Nordisk in Q1 2024 and has held it in 4 quarters since.
  • Belmont Capital's Novo Nordisk position peaked at $83.9K in Q2 2024.
  • 1,482 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Belmont Capital's 13F filing for Q2 2025, filed 12 Aug 2025.